Board of Directors
Ms. Dorchak joined the Board of Directors in January 2020. On July 31, 2018 Ms. Dorchak was appointed as a director of ANSYS, Inc. and on June 18, 2019, she was appointed as a director at GlobalFoundries. On November 20, 2019 Ms. Dorchak was appointed as a director of Viavi Solutions, Inc., a network test, measurement and assurance technology company. She also served from 2014 to March 2020 as an Operating Advisor to OMERS Private Equity, a private equity investment fund for a Canadian pension plan. Ms. Dorchak served as a director of Mellanox Technologies, Ltd. from July 2009 until its acquisition by NVIDIA Corporation (Nasdaq: NVDA) in April 2020, and from June 2018 to June 2019 she served as a director of Quantenna Communications, Inc. (QTNA). Ms. Dorchak was Executive Vice President and General Manager of Global Business for Spansion, Inc., a Sunnyvale, California based flash memory provider, from April 2012 to June 2013. From January 2009 until September 2010, when it was acquired by Red Bend Software, Ms. Dorchak was the chief executive officer and vice chairman of VirtualLogix, Inc., a Sunnyvale, California based provider of virtualization software for wireless and embedded devices. Prior to VirtualLogix, Inc., she served as chairman and chief executive officer of Intrinsyc Software International, Inc., a product development company of hardware, software, engineering and production services, from August 2006 to November 2008 where she had also served as an independent director September 2003 to December 2004. Ms. Dorchak was an executive at Intel Corporation from 2001 to 2006, including serving as vice president and chief operating officer of Intel Corporation's Communications Group; vice president and general manager of Intel's Consumer Electronics Group; and vice president and general manager of the Broadband Products Group. Prior to her tenure at Intel Corporation, she served as chairman and chief executive officer of Value America, Inc., an online retailer, from September 1999 to November 2000 and president from September 1998 to August 1999. From 1974 to 1998, Ms. Dorchak worked for IBM Corporation (" IBM "), a global technology and consulting corporation, both in Canada and later in Raleigh, North Carolina, where she held executive positions with IBM's Personal Systems Group, including directorships with the Ambra Systems Group and IBM PC North America.
Ms. Whitaker joined the Board of Directors in December 2013. Since October 2018, she has served as the Chief Executive Officer of Dance Biopharm Holdings, Inc., a clinical stage pharmaceutical and medical device company. Ms. Whitaker started her healthcare career in 1991 as a sales representative with The Upjohn Company, now Pfizer, Inc. (NYSE: PFE). She subsequently transitioned to GlaxoSmithKline PLC (NYSE: GSK) in 1992 where she rose in the leadership ranks to become a member of the global management team as the Global Head of the Leadership and Organization Development Centre of Excellence and ultimately served as the Senior Vice President and Business Unit Head for the Cardiovascular, Metabolic, and Urology franchises from September 2009 to September 2011. Ms. Whitaker joined Sanofi SA (Euronext Paris: SAN-FR) in 2011 where she served through August 2014 as the President of the North America Region and CEO of Sanofi US, LLC, where she led more than 5,000 employees to deliver revenues exceeding $16 billion annually. Ms. Whitaker served as the CEO and President of Synta Pharmaceuticals, Inc. (NASDAQ: SNTA) an oncology focused late stage pharmaceutical development company, which is now Madrigal Pharmaceuticals (NASDAQ: MDGL), from September 2014 to April 2015. She joined Bausch Healthcare Companies (NYSE: BHC) in May 2015 and served through January 2017 as Executive Vice President and Company Group Chairman for the global branded pharmaceutical segment where she notably led the successful integration of two multi-billion dollar businesses, Salix Pharmaceuticals and Dendreon. In 2017, Ms. Whitaker transitioned to the early stage biotech sector and helped build Novoclem Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, focused on developing therapies to treat people living with severe, chronic respiratory diseases. Prior to joining Dance Biopharm Holdings, Inc., starting in April 2018, Ms. Whitaker served as Managing Partner for Anne Whitaker Group, LLC, a consultant and professional service firm focused primarily on advising biotech and specialty pharmaceutical companies with commercial and product development strategy.
Ms. Whitaker previously served on the board of publicly traded Synta Pharmaceuticals, Inc. (NASDAQ: SNTA), now Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). Ms. Whitaker is currently an independent director on the board of two additional publicly traded companies, Mallinckrodt, Plc (NYSE: MKN), a specialty pharmaceutical company, and Vectura Group, Plc (London Exchange: VEC-GB), a pharmaceutical and medical device company. She was appointed in 2018 by the Governor of Alabama to serve as a Trustee for the University of North Alabama.